Fig. 4.

Survival of mice treated with sunitinib after intravenous injection of tumour cells. a Schematic diagram of dosing schedules tested. Balb/c mice were injected intravenously with 4T1-luc or RENCA-luc tumour cells and then treated with vehicle, 30, 60 or 120 mg/kg/day sunitinib daily for only 7 days (short term therapy) or daily until they became moribund (continuous dosing schedule). b, c Kaplan–Meier analysis of survival for 4T1-luc tumour bearing mice treated with vehicle or sunitinib under the dosing schedules shown in a. The two graphs show results from the same experiment, but survival of mice treated with sunitinib for 7 days (b) or treated with sunitinib continuously (c) have been presented as separate graphs for clarity. *P = 0.003, n = 8 mice per treatment group. d Kaplan–Meier analysis of survival for RENCA-luc tumour bearing mice treated with vehicle or sunitinib under the dosing schedules shown in a. *P = 0.01, **P = 0.0004, ***P = 0.0001, n = 8 mice per treatment group